Evaluation of Child Cases Admitted for Tick Bite and Tick Species in İstanbul

Aim:The Crimean-Congo Haemorrhagic Fever (CCHF) is a tick-borne infection that has a high mortality. In Turkey, the total number of cases reported between 2002-2014 was 9.069 and 440 of them died. The aim of this study is to evaluate the demographic characteristics of the children with the complaint of tick bite and to determine the species of the ticks seen in İstanbul.Materials and Methods:A hundred sixty two tick bite cases were analyzed with respect to demographic, clinical and laboratory findings between January and December 2014. The blood samples for whole blood count, prothrombin time, activated partial thromboplastin time, alanine aminotransferase, aspartate aminotransferase and creatinine were obtained from all cases and they were followed up for 10 days. The ticks removed from patients were classified by the Department of Parasitology in the Veterinary Faculty of İstanbul University.Results:The mean age of the patients was 6.1±3.7 years and 76% of them were male. Eighty four (52%) of the cases had additional complaints other than tick bite. The most frequently complaints were nausea/vomiting (26%), fever (19%) and cough (14%). We found that 34 (20%) of them had abnormal laboratory results such as elevated liver enzymes, leukocytosis, leukopenia, thrombocytopenia and prolonged prothrombin time. August was the month in which most patients applied (56 cases, 34%). The regions of body that were most bitten by the ticks were the extremities (35.8%). The total number of larvae, nymphs and adult ticks were found as 4, 88 and 14 respectively.Conclusion:This study showed that the tick species in the İstanbul province were largely different from the species causing CCHF. Although the incidence of CCHF in İstanbul is lower than in other regions of Turkey, children and their families who live in or travel to rural areas in Istanbul should be informed about this disease

The assessment in terms of QBO of NeQuick 2 model

The NeQuick 2 model which is a model calculated to ionospheric parameter was evaluated in terms of the stratospheric QBO. The relationship with QBO of the difference (ΔNmF1) was investigated by the multiple regression analysis model. ΔNmF1 defined as the difference (ΔNmF1 = NmF1measured − NmF1NeQuick 2) between the measured value from ionosonde and calculated value through the NeQuick 2 model of maximum electron density of the F1 region (NmF1). This investigation showed that the relationship at solar maximum case is stronger than the relationship at solar minimum case both in Darwin and in Learmonth stations. In solar minimum case, there are negative correlations between QBO and ΔNmF1 at both stations. In Darwin station, 67% of ΔNmF1 changes in case of solar maximum, 35% of ΔNmF1 changes in case of solar minimum can arise from the QBO. In Learmonth station, 51% of ΔNmF1 changes in case of solar maximum, 30% of ΔNmF1 changes in case of solar minimum can arise from the QBO. The results showed that the addition of QBO to the NeQuick 2 model would allow making calculations closing to actual data especially in the equator region of this model. Keywords: NeQuick 2 Model, QBO, Ionospheric F1 region, Electron densit

Effect of early atopic sensitization in children aged 0–2 years on the development of asthma symptoms at 9–11 years of age

© 2022, Children's Hospital, Zhejiang University School of Medicine.Background: Personal genetic predisposition and early life environmental factors are important for the development of childhood asthma. We aimed to search whether egg, milk and mite sensitizations at 0–2 years old are risk factors for asthma symptoms at 9–11 years old. Methods: A total of 210 wheezer children who had specific immunoglobulin (Ig) E in 2010–2012 were included in the study (followed by pediatric allergy). Patients were divided into non-atopic (group 1, n = 157) and atopic patients [groups 2–7, n = 53 (5 patients were in both group 4 and group 5)] based on sensitizations. Using the International Study of Asthma and Allergy in Childhood questionnaire, current wheeze (CW, 2nd question), exercise wheezing (EW, 7th question), and dry cough (DC, 8th question) were surveyed. Also, parental allergies, eczema at 0–2 years, current eosinophil percentage and total IgE were recorded. Results: Eczema was observed as an important risk factor [CW: odds ratio (OR) = 2.83, 95% confidence interval (CI) = 1.54–5.23, P ≤ 0.001; EW: OR = 2.71, 95% CI = 1.33–5.54, P = 0.006; DC: OR = 3.03, 95% CI = 1.47–6.25, P = 0.003], whereas having no atopic sensitization at 0–2-year-old (group 1) was found as a significant protective factor for asthma at 9–11 years old (CW: OR = 0.32, 95% CI = 0.15–0.70, P = 0.004; EW: OR = 0.21, 95% CI 0.10–0.44, P ≤ 0.001; DC: OR = 0.25, 95% CI = 0.10–0.59, P = 0.002). Conclusion: Early personal eczema is a significant risk factor for the development of asthma symptoms at 9–11 years old, whereas not having an allergic sensitization at 0–2 years old (group 1) is an important protective factor

Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study

..

DENOSUMAB TÜRKİYE VERİLERİ: KRONİK BÖBREK HASTALIĞI’NIN DENOSUMAB SONLANIM NOKTALARINA ETKİSİ; TÜRK ONKOLOJİ GRUBU(TOG) ÇALIŞMAS

Amaç: Denosumab, kemik remodellingini düzenleyen önemli bir ligand olan NFkB ligandının (RANKL) reseptör aktivatörünü spesifik olarak bağlar ve inaktive eder. Tümör hücreleri tarafından uyarılan kemik yıkım döngüsünü azaltarak İİÖ’yü önlemede etkin bir ajandır. Denosumab, ağırlıklı olarak retiküloendotelyal sistem yoluyla temizlenen bir monoklonal antikordur. Denosumab böbrekler tarafından atılmadığından, böbrek fonksiyonunun izlenmesi ve önceden var olan böbrek yetmezliği için doz ayarlaması gerekli değildir ve önerilmemektedir. Gereç-Yöntem: Ocak 2011-Aralık 2021 tarihleri arası tüm solid organ malignitesi olan hastalarda denosumab kullanan hastaların, bu tedaviyi alma süresi, yan etkilerinin sıklığı ve derecesi retrospektif olarak incelendi.Türkiye Onkoloji Grubu(TOG) projesi kapsamında toplam 17 merkezden 266 hasta incelendi.11 hasta verileri ulaşılamadığı için çıkarıldı. Hastalar KBH’ı olanlar ve olmayanlar olarak iki gruba ayrılıp incelendi, yan etkileri, görülme sıklıkları, iskelet ilişkili olayların sıklığı ve sağkalıma etkileri incelendi. Bulgular: Çalışmaya alınan hastaların 157(%59.5)’si kadındı. Ortalama takip süresi 64.86(57.19-72.53) aydı. Grade 3 toksiste toplam 18 hastada görüldü. Bunların 15’inde hipokalsemi,2’sinde kreatinin artışı, 1’nde osteonekroz görüldü. GFR 60’ın altında olan hastalar ile grade 3 toksisite ilişkisi anlamlı olarak görüldü(18 grade 3 toksiste’nin 8’inde GFR 60’ın altındaydı.p&lt;0.001) Grade 3 toksiste sağkalım ilişkisine bakıldığında grade 3 toksiste gelişen hastalarda sağkalım oldukça kısaydı(36.4 ay v 165.38 ay, p&lt;0.001) Sonuç: Denosumab alan ve GFR’si 60’ın altında olan hastalarda grade 3 yan etki görülme oranı ve buna bağlı olarak iskelet ilişkili olay görülme sıklığı daha fazladır. Anahtar Kelimeler: denosumab, glomerüler filtrasyon hızı, hipokalsemi</p

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Abstract Background The optimal treatment for metastatic colorectal cancer (mCRC) after the second line is still controversial. Regorafenib has been the standard of care in this setting as it improved overall survival (OS) compared to placebo. In real-world practice chemotherapy rechallenge is also a preferred option even though supporting evidence is not enough. We aim to compare the efficacy of regorafenib and 5-fluorouracil-based (5-FU) rechallenge treatment in the third line setting of mCRC. Methods In this retrospective multi-institutional trial, mCRC patients from 21 oncology centers who progressed after 2 lines of chemotherapy were analyzed. Patients who were treated with regorafenib or rechallenge therapy in the third-line setting were eligible. Rechallenge chemotherapy was identified as the re-use of the 5-FU based regimen which was administered in one of the previous treatment lines. OS, disease control rate (DCR), progression free survival (PFS) and toxicity were analyzed. Results Three hundred ninety-four mCRC patients were included in the study. 128 (32.5%) were in the rechallenge, and 266 (67.5%) were in the regorafenib group. Median PFS was 5.82 months in rechallenge and 4 months in regorafenib arms (hazard ratio:1.45,95% CI, p = 0.167). DCR was higher in the rechallenge group than regorafenib (77% vs 49.5%, respectively, p =  < 0.001). Median OS after the third-line treatment was 11.99 (95% CI, 9.49–14.49) and 8.08 months (95% CI, 6.88–9.29) for rechallenge and regorafenib groups, respectively (hazard ratio:1.51, 95% CI, p < 0.001). More adverse effects and discontinuation were seen with regorafenib treatment. Conclusion Our study revealed that higher disease control and OS rates were achieved with rechallenge treatment compared to regorafenib, especially in patients who achieved disease control in one of the first two lines of therapy